NASDAQ: TPST
Tempest Therapeutics Inc Stock Ownership - Who owns Tempest Therapeutics?

Insider buying vs selling

Have Tempest Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Matthew AngelCEO and President2026-03-24231,482$2.16
$500.00kBuy
Matthew AngelCEO and President2026-03-24231,482$2.16
$500.00kBuy

1 of 1

TPST insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when TPST insiders and whales buy or sell their stock.

TPST Shareholders

What type of owners hold Tempest Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Matthew Angel90.07%13,337,047$14.54MInsider
Michelle Dipp53.75%7,959,182$8.68MInsider
Richard Aldrich35.22%5,214,762$5.68MInsider
Christoph H. Westphal30.58%4,527,348$4.93MInsider
Versant Venture Capital VI LP23.69%3,507,056$3.82MInsider
Bessemer Venture Partners VII LP16.15%2,392,034$2.61MInsider
Thomas Woiwode14.75%2,183,788$2.38MInsider
Versant Vantage II LP14.31%2,118,644$2.31MInsider
Longwood Fund LP12.42%1,839,689$2.01MInsider
Forest Baskett11.93%1,766,407$1.93MInsider

1 of 3

TPST vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
TPST1.22%98.78%Net Buying
QNRX1.69%6.75%Net Buying
CTXR3.63%2.06%
HOWL25.50%74.50%Net SellingNet Selling
CMMB0.06%2.91%Net BuyingNet Buying

Tempest Therapeutics Stock Ownership FAQ

Who owns Tempest Therapeutics?

Tempest Therapeutics (NASDAQ: TPST) is owned by 5.31% institutional shareholders, 430.92% Tempest Therapeutics insiders, and 0.00% retail investors. Matthew Angel is the largest individual Tempest Therapeutics shareholder, owning 13.34M shares representing 90.07% of the company. Matthew Angel's Tempest Therapeutics shares are currently valued at $14.54M.

If you're new to stock investing, here's how to buy Tempest Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.